Multisystem inflammatory syndrome in adult COVID-19 patients

To the Editor: As we pass the peak of the COVID-19 epidemic in South Africa (SA), we want to remind healthcare workers to have heightened vigilance regarding a multisystem inflammatory syndrome reported in children and adolescents (MIS-C). In Europe and North America (where this syndrome was initially reported), it is common practice for adolescents to be admitted to paediatric wards, but in SA, those >13 years of age are conventionally admitted to adult wards. Since this life-threatening syndrome is mainly described in children, we are concerned that this seemingly rare condition may be missed by clinicians who treat adolescents and adults.

At Tygerberg Hospital, Cape Town, SA, the first paediatric patient was diagnosed with MIS-C on 4 July 2020, and a number of cases followed thereafter. The first three patients in the adult service, aged 15, 22 and 27 years, were diagnosed between 13 and 20 August 2020 (presenting within a single week). All three met the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria for MIS-C, although prior COVID-19 infection could not be proven owing to unavailability of antibody tests. They presented with mucocutaneous involvement resembling a viral exanthem, cracked lips, sore throat, non-exudative conjunctivitis, oedema, abdominal pain, severe myocardial dysfunction resulting in shock, confusion, meningoencephalopathy and acute kidney injury. Despite having markedly raised inflammatory markers, no definite source of sepsis was found. They were treated with intravenous immunoglobulin (IVIG) and corticosteroids, with remarkable clinical, biochemical and echographic improvements.

MIS-C cases are described to occur after the peak of the epidemic, and resemble both Kawasaki disease (familiar to paediatricians) and toxic shock, but are a distinct entity. The condition is characterised by shock and/or other features of severe organ dysfunction with inflammation including severe abdominal pain, conjunctival injection, rash and notably renal and cardiac dysfunction. Laboratory features include raised inflammatory markers, abnormal coagulation profiles and markers of organ dysfunction. The diagnosis is by exclusion of sepsis, toxic shock and autoimmune diseases. The patients must have compatible clinical features, laboratory markers and evidence of prior COVID-19 diagnosis (as manifested by a current/prior positive SARS-CoV-2 diagnosis by polymerase chain reaction, or contact with a person who has COVID-19, or a positive antibody test). This currently poses a challenge in Africa as access to the COVID-19 antibody test is limited.

Management is supportive and includes intensive care if required. Specific treatment is yet to be determined, but the current protocol includes IVIG, corticosteroids and the use of biological agents such as tocilizumab, anakinra or infliximab. Typically, patients respond rapidly to the treatment (within a matter of days). Failure to administer treatment is associated with mortality. In conclusion, clinicians should have an increased index of suspicion and be familiar with the proposed case definitions to identify this syndrome early and be aware of its variable manifestations. Although antibody tests are not yet widely available, the diagnosis can be made in low-resource and highly endemic settings by careful and systematic analysis of clinical clues. Prompt recognition and collaboration from various medical and paediatric disciplines may be the key to optimal patient care, as in our case.

Acknowledgements. The authors wish to acknowledge the staff and COVID-19 teams of Khayelitsha and Tygerberg Hospitals.

Author contributions. AP, EHL and SL drafted the letter. HR and CFK reviewed the manuscript. All authors contributed equally to the final manuscript.

A Parker
Division of General Medicine and Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

E H Louw, U Lalla, C F N Koegelenberg, B W Allwood
Division of Paediatrics, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

H Rabie
Division of Paediatric Infectious Diseases, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

S J Taljaard
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

S Lahri
Division of Emergency Medicine, Department of Family Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa


